To evaluate the efficacy and safety of naxitamab in patients with refractory Ewing's sarcoma.
Key facts
- Where
- Warsaw és Wroclaw, LengyelországSee the 2 sites
- Phase
- 2. fázis
Where in Lengyelország
- Instytut Matki i DzieckaWarsaw, LengyelországTaking people
- Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we WroclawiuWroclaw, LengyelországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Instytut Matki I Dziecka
- Trial code
- EU 2024-514441-11-00
- Record updated
- 2024. augusztus 6.
- Original description
Safety assessment of the addition of naxitamab to standard 3-week chemotherapy (CHT) in patients with refractory Ewing's sarcoma (ES)Read full original descriptionShow less
Safety assessment of the addition of naxitamab to standard 3-week chemotherapy (CHT) in patients with refractory Ewing's sarcoma (ES)
Inclusion: Histologically proven Ewing sarcoma of the bone or soft tissues; Consent to the use of effective contraception throughout the period of the study and a minimum of 1 year after discontinuation of study treatment in patients at puberty and sexual maturity; Subject's archival tumour sample (formalin-fixed, paraffinembedded; FFPE) available for evaluation of GD2 expression; Documented disease progression (during or after completion of at least one line treatment) or any subsequent recurrence; GD2 positive tumor assessed by IHC; Age ≥ 2 years and ≤ 21 years; Life expectancy of at least 12 weeks from the time informed consent was signed; Previous systemic anticancer treatment completed ≥ 3 weeks, major surgery ≥ 2 weeks, and radiation therapy ≥ 4 weeks prior to study enrollment; Recovered from adverse effects of prior surgery, radiotherapy, or anti-neoplastic therapy at the discretion of the investigator; Signing of informed consent for trial participation (including for naxitamab treatment) according with current legal regulations.
Exclusion: Requirement, or likely requirement, for corticosteroids at doses >10 mg prednisolone (or equivalent) per day or other immunosuppressive agents; Planning to become pregnant (while being treated with IT or naxitamab), pregnancy or breastfeeding; Previous treatment with an anti-GD2 antibody; Simultaneous treatment with other drugs which might interact with naxitamab or IT regimen; Persistent toxicity related to prior therapy, making it impossible to treat with naxitamab; Failure to meet any of the inclusion criteria; Diagnosis of other malignancies before study inclusion; Hypersensitivity to the study drugs or any of their ingredients (covers IT and naxitamab); Other acute or persistent disorders, behaviors or abnormal laboratory test results, which might increase the risk related to the participation in this clinical trial or to taking the study drug, or which might influence the interpretation of the study results, or which, in the investigator's opinion, disqualify a patient from participating in the trial; Significant cardiac conduction abnormalities, including known familial prolonged QT syndrome, or screening QTc >480 msec; Symptoms of congestive heart failure or left ventricular ejection fraction <50%; Not eligible to IT; Inadequate pulmonary function defined as evidence of dyspnea at rest, exercise intolerance, and/or chronic oxygen requirement. In addition, room air pulse oximetry < 94% and/or abnormal pulmonary function tests if these assessments are clinically indicated.